Vitrolife tecknar samarbetsavtal med University of Melbourne gällande utveckling av stamcellsmedier

13:00 / 14 juni 2010 / Vitrolife

Vitrolife har ingått ett tvåårigt samarbetsavtal med University of Melbourne gällande samarbete med stamcellsexpertis inom utveckling av kliniska stamcellsmedier.

"Regenerativ medicin är ett område som växer starkt både inom industrin och akademin. Idag finns ett icke tillgodosett behov av högkvalitativa kliniskt graderade stamcellsmedier ", säger Magnus Nilsson, VD för Vitrolife. "University of Melbourne har unik kompetens inom stamceller, framför allt när det gäller pluripotenta stamceller och är därför en värdefull resurs för att utveckla rätt produkter för en snabbt växande marknad", säger Anna Mårtensson, chef för affärsområde stamceller på Vitrolife.

Göteborg 14 juni 2010

Magnus Nilsson

Verkställande direktör

Kontaktpersoner:

VD Magnus Nilsson, telefon 031-721 80 61

Ekonomi- och informationschef Eva Nilsagård, telefon 031-721 80 13

________________________________________________________________________________________________________________________________ Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes. Vitrolife today has approximately 170 employees and the company's products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are housed in Sweden and USA. The Vitrolife share is listed on NASDAQ OMX Nordic Exchange, Small Cap. ________________________________________________________________________________________________________________________________ Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: . Homepage: www.vitrolife.com. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.